Supernus Pharmaceuticals (SUPN) Announces Issuance Of Third US Patent Protecting Oxtellar XR®
1/7/2014 9:30:27 AM
ROCKVILLE, Md., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a third patent (number 8,617,600) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR®, its novel once-daily extended-release oxcarbazepine product. The patent was issued by the USPTO on December 31, 2013. It provides protection for the product with expiration that is no earlier than 2027.
Help employers find you! Check out all the jobs and post your resume.
comments powered by